Breaking Finance News

A statement released earlier today by Cantor Fitzgerald about Illumina (NASDAQ:ILMN) bumps down the target price to $155.00

Cantor Fitzgerald dropped the price target of Illumina (NASDAQ:ILMN) to $155.00 indicating a possible downside of -0.16%.

On 10/3/2016, Vetr Inc. released a statement for Illumina (NASDAQ:ILMN) bumped up the target price from $0.00 to $198.61 that suggested an upside of 0.09%.

Boasting a price of $184.85, Illumina (NASDAQ:ILMN) traded 0.00% even on the day. With the last stock price close up 18.07% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Illumina has recorded a 50-day average of $175.01 and a two hundred day average of $156.56. Volume of trade was down over the average, with 2,633 shares of ILMN changing hands under the typical 1,026,110

Performance Chart

Illumina (NASDAQ:ILMN)

With a total market value of $0, Illumina has price-earnings ratio of 63.30 with a one year low of $127.10 and a one year high of $196.47 .

A total of 19 equity analysts have released a ratings update on ILMN. Four equity analysts rating the company a strong buy, four equity analysts rating the company a buy, fifteen equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $154.53.

Brief Synopsis About Illumina (NASDAQ:ILMN)

Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.